Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Identifying Drivers of Triple Negative Breast Cancer within Arm-Level Somatic Copy Number Alterations
EF 2023-24
Résumé
One in eight women in Canada is diagnosed with Breast cancer, leading to thousands of deaths each year. Triple Negative Breast Cancer (TNBC) is one of the most aggressive cancer types with an early age of onset, significant metastatic potential, and poor survival rate. TNBC tumours do not express hormonal receptors, making them resistant to classical hormonal therapy and harder to treat with conventional chemotherapy. Understanding the genetic basis driving the development and progression of TNBC is essential for the innovation of current therapies and treatment options. Through a multi-faceted approach, we identified a new potential therapeutic target for TNBC: Receptor Interacting Protein Kinase 4 (RIPK4), a gene controlling many cellular pathways involved in growth and development. Our research aims to test the therapeutic efficacy of targeting RIPK4 in TNBC and to better understand the mechanisms by which this gene promotes breast cancer progression. We hypothesize that RIPK4 promotes tumour development pathways while inhibiting the function of the immune system in cancer cell clearance. The research project is multidisciplinary as it combines techniques and knowledge from the fields of immunology, genetics, and molecular biology, allowing for a thorough exploration of the genetic basis of TNBC. Understanding the molecular and genetic factors underlying TNBC can lead to the development of personalized treatments, reducing unnecessary side effects and improving the overall quality of life for patients. Furthermore, findings from TNBC research can inform public health initiatives, screening programs, and healthcare policies, leading to better preventive measures and early intervention strategies for breast cancer.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505831
Name
Ali Mariam
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying Drivers of Triple Negative Breast Cancer within Arm-Level Somatic Copy Number Alterations
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Arm-Level Somatic Copy Number Alterations (Scnas); Cancer Driver Mutations; Cancer Genome Atlas (Tcga); Immunotherapy; Lung-Metastatic Tnbc Model; Metastasis; Murine Model; Ripk4; Triple-Negative Breast Cancer (Tnbc); Tumour Immune Microenvironment
Abstract
One in eight women in Canada is diagnosed with Breast cancer, leading to thousands of deaths each year. Triple Negative Breast Cancer (TNBC) is one of the most aggressive cancer types with an early age of onset, significant metastatic potential, and poor survival rate. TNBC tumours do not express hormonal receptors, making them resistant to classical hormonal therapy and harder to treat with conventional chemotherapy. Understanding the genetic basis driving the development and progression of TNBC is essential for the innovation of current therapies and treatment options. Through a multi-faceted approach, we identified a new potential therapeutic target for TNBC: Receptor Interacting Protein Kinase 4 (RIPK4), a gene controlling many cellular pathways involved in growth and development. Our research aims to test the therapeutic efficacy of targeting RIPK4 in TNBC and to better understand the mechanisms by which this gene promotes breast cancer progression. We hypothesize that RIPK4 promotes tumour development pathways while inhibiting the function of the immune system in cancer cell clearance. The research project is multidisciplinary as it combines techniques and knowledge from the fields of immunology, genetics, and molecular biology, allowing for a thorough exploration of the genetic basis of TNBC. Understanding the molecular and genetic factors underlying TNBC can lead to the development of personalized treatments, reducing unnecessary side effects and improving the overall quality of life for patients. Furthermore, findings from TNBC research can inform public health initiatives, screening programs, and healthcare policies, leading to better preventive measures and early intervention strategies for breast cancer.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ali, Mariam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~